CANCER HAS BEEN CURED
Ivermectin & Fenbendazole cure cancer.
Pass it on.
BREAKING NEWS: First-in-the-World Ivermectin, Mebendazole and Fenbendazole Protocol in Cancer has been peer-reviewed and published on Sep.19, 2024!
The future of Cancer Treatment starts NOW.
My thanks to lead authors Ilyes Baghli and Pierrick Martinez for their incredible inspired work, FLCCC’s Dr.Paul Marik for his extensive work on repurposed drugs and every co-author who worked hard to bring this paper to life.
I hope that this peer-reviewed paper lays the groundwork for a brand new future for Cancer Treatment.
Many of you know that I have been helping thousands of Cancer patients with high dose Ivermectin, Mebendazole, and Fenbendazole
Two MASSIVE COVID shot studies involving 8.7 MILLION people confirm Fauci and Gates injected the world with CANCER:
BREAST CANCER: +54%
PROSTATE CANCER: +69%
LUNG CANCER: +53%
BLADDER CANCER: +62%
COLON CANCER: +35%
STOMACH CANCER: +34%
THYROID CANCER: +35%
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health@McCulloughFund@IIAR_Journals@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly@FosterCoulson
@Corriere Propaganda, pura propaganda. Ci sono migliaia di petroliere in giro per il mondo ma guarda caso bastano quelle bloccate in medio oriente per riproporre restrizioni a cui gli allocchi abboccheranno
@LegaSalvini Prorpio non ce la fate eh? Ma quali punti, remigrazione per chi delinque, non c'è bisogno di spettacolarizzare sempre tutto e considerare un uomo un numero. Prima o poi ci saranno leggi elettorali che non vi mandano in politica senza passare per la VERA volontà popolare
@benq_antonio Evidentemente non sanno cosa succedeva in naja. Anno perso, solo servizi inutili senza alcun tipo di formazione, e di insegnamento a vivere. RIDICOLI QUELLI CHE LA SOSTENGONO SENZA SAPERE